Log in

NASDAQ:STMLStemline Therapeutics Stock Price, Forecast & News

$11.86
+0.10 (+0.85 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.73
Now: $11.86
$11.89
50-Day Range
$4.75
MA: $8.43
$12.22
52-Week Range
$3.21
Now: $11.86
$18.22
Volume761,900 shs
Average Volume3.23 million shs
Market Capitalization$622.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34
Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Read More
Stemline Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STML
CUSIPN/A
Phone646-502-2311

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.22 million
Book Value$2.81 per share

Profitability

Net Income$-76,820,000.00
Net Margins-150.30%

Miscellaneous

Employees92
Market Cap$622.77 million
Next Earnings DateN/A
OptionableOptionable

Receive STML News and Ratings via Email

Sign-up to receive the latest news and ratings for STML and its competitors with MarketBeat's FREE daily newsletter.

Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions

How has Stemline Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Stemline Therapeutics' stock was trading at $4.69 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, STML shares have increased by 152.9% and is now trading at $11.86. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Stemline Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Stemline Therapeutics.

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics Inc (NASDAQ:STML) posted its earnings results on Tuesday, May, 12th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. Stemline Therapeutics had a negative return on equity of 48.14% and a negative net margin of 150.30%. View Stemline Therapeutics' earnings history.

What price target have analysts set for STML?

8 equities research analysts have issued 12-month price targets for Stemline Therapeutics' stock. Their forecasts range from $8.00 to $12.50. On average, they expect Stemline Therapeutics' share price to reach $11.31 in the next year. This suggests that the stock has a possible downside of 4.6%. View analysts' price targets for Stemline Therapeutics.

Has Stemline Therapeutics been receiving favorable news coverage?

News articles about STML stock have trended somewhat positive on Saturday, according to InfoTrie. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Stemline Therapeutics earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutStemline Therapeutics.

Who are some of Stemline Therapeutics' key competitors?

What other stocks do shareholders of Stemline Therapeutics own?

Who are Stemline Therapeutics' key executives?

Stemline Therapeutics' management team includes the following people:
  • Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 53)
  • Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 59)
  • Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 54)
  • Mr. Robert Francomano, Sr. VP & Global Head of Commercial
  • Mr. John A. Salvagno, Sr. VP of Quality & Operations

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

Who are Stemline Therapeutics' major shareholders?

Stemline Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.42%), The Manufacturers Life Insurance Company (4.93%), State Street Corp (4.20%), Empire Life Investments Inc. (1.87%), Stonepine Capital Management LLC (1.69%) and Geode Capital Management LLC (1.30%). Company insiders that own Stemline Therapeutics stock include Alan S Forman, David Gionco, Ivan Bergstein, Kenneth Hoberman and Robert Francomano. View institutional ownership trends for Stemline Therapeutics.

Which major investors are selling Stemline Therapeutics stock?

STML stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Rhenman & Partners Asset Management AB, Morgan Stanley, UBS Group AG, Telemetry Investments L.L.C., Victory Capital Management Inc., Victory Capital Management Inc., and Virtus ETF Advisers LLC. Company insiders that have sold Stemline Therapeutics company stock in the last year include David Gionco, Ivan Bergstein, Kenneth Hoberman, and Robert Francomano. View insider buying and selling activity for Stemline Therapeutics.

Which major investors are buying Stemline Therapeutics stock?

STML stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Empire Life Investments Inc., Cambiar Investors LLC, Bullseye Asset Management LLC, Geode Capital Management LLC, Russell Investments Group Ltd., Los Angeles Capital Management & Equity Research Inc., and Weiss Multi Strategy Advisers LLC. View insider buying and selling activity for Stemline Therapeutics.

How do I buy shares of Stemline Therapeutics?

Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Stemline Therapeutics' stock price today?

One share of STML stock can currently be purchased for approximately $11.86.

How big of a company is Stemline Therapeutics?

Stemline Therapeutics has a market capitalization of $622.77 million and generates $43.22 million in revenue each year. The biopharmaceutical company earns $-76,820,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe.

What is Stemline Therapeutics' official website?

The official website for Stemline Therapeutics is www.stemline.com.

How can I contact Stemline Therapeutics?

Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.